SATPAL RATHOUR: Open Payments
NPI 1972834091 · SHIRLEY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,105 in 90 payments from 11 companies in 2025. Trend: 2023 $1,482 · 2024 $1,479 · 2025 $2,105
Food & beverage: $2,105
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $456 |
| Vanda Pharmaceuticals Inc. | 20 | $363 |
| Axsome Therapeutics, Inc. | 10 | $292 |
| Teva Pharmaceuticals USA, Inc. | 11 | $245 |
| Alkermes, Inc. | 9 | $244 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $188 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| Lundbeck LLC | 4 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| E.R. Squibb & Sons, L.L.C. | 1 | $37 |
Products named: INGREZZA, Auvelity, ARISTADA, FANAPT, REXULTI, AUSTEDO XR, CAPLYTA, HETLIOZ.
Industry payments across NY — which companies pay providers there.
